D.E. Shaw & Co
SRRA

D.E. Shaw & Co’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

D.E. Shaw & Co’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-435
Closed -$30K – 3958
2019
Q1 		$30K Sell
435
-40
-8% -$2.57K ﹤0.01% 3532
2018
Q4 		$25K Sell
475
-98
-17% -$6.26K ﹤0.01% 3703
2018
Q3 		$39K Buy
+573
New +$52K ﹤0.01% 3665
2017
Q4 		– Sell
-1,058
Closed -$66K – 3800
2017
Q3 		$66K Sell
1,058
-215
-17% -$12.6K ﹤0.01% 3391
2017
Q2 		$60K Sell
1,273
-857
-40% -$43.7K ﹤0.01% 3298
2017
Q1 		$130K Sell
2,130
-118
-5% -$6.86K ﹤0.01% 3176
2016
Q4 		$134K Buy
2,248
+1,406
+167% +$87.7K ﹤0.01% 3328
2016
Q3 		$61K Buy
+842
New +$65.1K ﹤0.01% 3315

Other funds holding SRRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co's SRRA Position: Q2 2019 in Review

D.E. Shaw & Co sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2019, closing a stake of 435 shares — an estimated $30K sold.

D.E. Shaw & Co first reported a position in SRRA in Q3 2016 and held it in 8 quarters. The position peaked at $134K in Q4 2016. 49 funds tracked by Wall St. Rank hold SRRA as of Q2 2019.

  • D.E. Shaw & Co reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • D.E. Shaw & Co sold 435 Sierra Oncology, Inc. Common Stock shares in Q2 2019, an estimated $30K.
  • D.E. Shaw & Co first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2016 and held it in 8 quarters.
  • D.E. Shaw & Co's Sierra Oncology, Inc. Common Stock position peaked at $134K in Q4 2016.
  • 49 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2019.

Based on D.E. Shaw & Co's 13F filing for Q2 2019, filed 14 Aug 2019.